A Platform for Simultaneous Expression of Anticancer Genes and Immune Checkpoint Inhibitors
US Patent Registration Secured; Global Patent Expansion Underway

Algonomics announced on July 9 that its anticancer gene therapy platform, "RZ-002," has received a patent registration decision in the United States.


With this patent secured, Algonomics has now obtained exclusive rights to this platform technology in the United States, the world's largest bio market, following previous patents in Korea, Japan, and Australia.


Algonomics Company Logo Image. Algonomics

Algonomics Company Logo Image. Algonomics

View original image

RZ-002 is a next-generation anticancer gene therapy platform based on an RNA replacement enzyme that simultaneously expresses anticancer genes and immune checkpoint inhibitors. It targets the telomerase reverse transcriptase (TERT) gene, which is expressed in cancer cells, thereby inducing the expression of anticancer genes exclusively in cancer cells to promote their destruction, while also expressing immune checkpoint inhibitors only in localized tumor areas to activate anticancer immunity. This design aims to minimize systemic side effects while maximizing anticancer efficacy.


This patent is notable for granting broad rights that impose no restrictions on the types or numbers of anticancer genes and immune checkpoint inhibitors used. As a result, various combinations of anticancer genes and immune checkpoint inhibitors are possible, allowing the platform technology to be applied to a wide range of cancer types.


Algonomics is currently seeking to secure global intellectual property rights, with patent applications for RZ-002 under review not only in the United States but also in Europe, China, and other major countries.


Seongwook Lee, CEO of Algonomics, stated, "Securing a patent for our next-generation anticancer platform in the US further strengthens our global intellectual property portfolio for the RNA replacement enzyme platform. We will accelerate development to provide effective treatment options to patients with intractable cancers through various combinations with anticancer genes."



The RZ-002 platform technology was selected for the "Innovative New Drug Pipeline Discovery Project" by the Ministry of Science and ICT in 2019, receiving over 2.1 billion won in government R&D funding for its development. Algonomics announced in May at the American Society of Gene and Cell Therapy (ASGCT 2026) that it had presented preclinical research results for RZ-002 targeting brain cancer, confirming superior safety and anticancer efficacy compared to conventional systemic administration of immune checkpoint inhibitors.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing